Vitamin D: a new approach to overcoming chemoresistance in prostate cancer

Castration-resistant prostate cancer (CRPC) presents a major therapeutic challenge in men due to the resistance that develops against standard treatments like docetaxel. Therefore, finding approaches to overcome this chemoresistance is a top priority. In this context, researchers are investigating vitamin D, known for its anti-inflammatory and anticancer properties.

This article explores the impact of vitamin D analogues (Xe4MeCF3) on docetaxel efficacy and chemoresistance in prostate cancer.